This page contains a Flash digital edition of a book.
42 Traditional medicine patents lead to enhanced drug discovery from natural products


Natural products are ripe for potential drug discovery and the life sciences sector is rich with traditional medicine patents. A growing reservoir of traditional medicine content is available, along with effi cient and productive search methods for exploring it. John Zabilski explains.


46 US patent law changes appear imminent


US patent reform looks like it may fi nally be coming. John Pegram and Mark Ellinger explain the proposed changes.


48 Patenting genes and diagnostics


As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look.


52 Attacking the validity of selection patents


The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.


56 The role of the function of DNA sequence before and after grant


Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.


60 The Brazilian pharmaceutical sector: a year in review


Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.


64 Patentability of dosage regimens in Europe


First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.


68 A revolution: biotech patents in India


It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains.


72 Recognising equivalence, reciprocity and respect


Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself. Homologation cannot be fully effective unless it is based on reciprocity and mutual respect. Hedwig Lindner and Manuel Morante explain.


76 Banning the patenting of biological materials in Australia: fact v fi ction


An Australian legislative bill could have grave consequences for the country’s life sciences industry and potentially, for patients as well. Tania Obranovich explains.


78 Windows of opportunity and closing doors at the EPO


There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the European Patent Offi ce approaches these inventions and the positives and negatives for the pharmaceutical industry.


80 Patenting life


A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.


www.worldipreview.com Life Sciences Intellectual Property Review 2011 5


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84